Key result
Structural and computational analyses of opicapone revealed unique dispersion interactions in the COMT binding pocket and a novel complex with SAH, suggesting it acts as a twofold inhibitor.
Structural analysis reveals that opicapone's unique sidechain interactions allow it to form a complex with SAH and COMT, suggesting a dual mechanism of COMT inhibition.
Opicapone's unique COMT interactions suggest dual inhibition; hypothesis-generating and requires human validation before clinical consideration.
A third-generation inhibitor of catechol O -methyltransferase (COMT), opicapone ( 1 ), has the 3-nitrocatechol scaffold as do the second-generation inhibitors such as entacapone ( 2 ) and tolcapone ( 3 ), but only 1 can sustainably inhibit COMT activity making it suitable for a once-daily regimen. These improvements should be attributed to the optimized sidechain moiety (oxidopyridyloxadiazolyl group) of 1 substituted at the 5-position of the 3-nitrocatechol ring. We analyzed the role of the sidechain moiety by solving the crystal structures of COMT/ S -adenosylmethionine (SAM)/Mg/ 1 and COMT/ S -adenosylhomocysteine (SAH)/Mg/ 1 complexes. Fragment molecular orbital (FMO) calculations elucidated that the dispersion interaction between the sidechains of Leu 198 and Met 201 on the β6β7-loop and the oxidopyridine ring of 1 were unique and important in both complexes. In contrast, the catechol binding site made a remarkable difference in the sidechain conformation of Lys 144. The ε-amino group of Lys 144 was outside of the catalytic pocket and was replaced by a water molecule in the COMT/SAH/Mg/ 1 complex. No nitrocatechol inhibitor has ever been reported to make a complex with COMT and SAH. Thus, the conformational change of Lys 144 found in the COMT/SAH/Mg/ 1 complex is the first crystallographic evidence that supports the role of Lys 144 as a catalytic base to take out a proton ion from the reaction site to the outside of the enzyme. The fact that 1 generated a complex with SAH and COMT also suggests that 1 could inhibit COMT twofold, as a typical substrate mimic competitive inhibitor and as a product-inhibition enhancer.
No takes yet. Share an insight, caveat, or question.
Takebe et al. (2023) studied this question. Opicapone was evaluated. Structural and computational analyses of opicapone revealed unique dispersion interactions in the COMT binding pocket and a novel complex with SAH, suggesting it acts as a twofold inhibitor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: